Managing Chronic Inflammation with Psoriasis

Health & Lifestyle
329

Listen to article (english)

Translate to Spanish or other 102 languages!

Although the exact cause of psoriasis is unknown, doctors consider it an immune-mediated inflammatory disease. This means that inflammation is at the root of this condition. Image for illustration purposes
Although the exact cause of psoriasis is unknown, doctors consider it an immune-mediated inflammatory disease. This means that inflammation is at the root of this condition. Image for illustration purposes

Medical News Today

- Advertisement -

Up to 3%Trusted Source of adults in the United States have psoriasis. It causes skin symptoms, such as raised plaques and discoloration, and can also affect other parts of the body, such as the joints and eyes.

Experts believe inflammation is the common factor that can affect these different areas.

Follow the link below to Medical News Today to read the full story:

- Advertisement -

https://www.medicalnewstoday.com/articles/psoriasis-and-chronic-inflammation

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Childhood Arthritis & What you Need to Know
Next article
Physical Activity & Self-Management Education Programs for Arthritis

More Articles

Sun Allergy Is Real: Signs, Causes, and How to Protect Your Skin

Is it possible to have a sun allergy? It may feel that way on a hot day, but for some people, that’s actually the case.

Beat the Summer Heat: Essential Hydration Tips

Summer heat has a way of sneaking up on you, making it easy to become dehydrated before you even realize you're thirsty.

STHS’ Transform Your Life Event Inspires Healthier Living Across the RGV

Whether you're making healthier food choices, becoming more active or focusing on your mental well-being, every positive change can help you live a longer, healthier and more fulfilling life.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.
- Advertisement -